Ciro Matsui

Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial

Riccardo Masson, Maria Mazurkiewicz-Bełdzińska, Kristy Rose et al. · The Lancet Neurology · 2022 · 96 citations · Full text

Type 1, Firefish Part 2, Rehabilitation +6

Intragenic variants in the <i>SMN1</i> gene determine the clinical phenotype in 5q spinal muscular atrophy

Rodrigo de Holanda Mendonça, Ciro Matsui, Graziela Jorge Polido et al. · Neurology Genetics · 2020 · 42 citations · Full text

Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience

Rodrigo de Holanda Mendonça, Graziela Jorge Polido, Ciro Matsui et al. · Journal of Neuromuscular Diseases · 2020 · 37 citations

Backgroundspinal Muscular Atrophy, Motor Neuron Disease, Neurological Disorder +18

Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy

Edmar Zanoteli, Alexandra Prufer de Queiroz Campos Araújo, Michele Michelin Becker et al. · Arquivos de Neuro-Psiquiatria · 2024 · 16 citations · Full text

Motor unit number index (MUNIX) in children and adults with 5q-spinal muscular atrophy: Variability and clinical correlations

Rodrigo de Holanda Mendonça, Ligia Maria Sotero Machado, Carlos Otto Heise et al. · Neuromuscular Disorders · 2021 · 10 citations